Life Biosciences reports interim ER-100 safety observations in three participants
Source publication date
Summary
Life Biosciences reported interim ER-100 Phase 1 observations in three participants with open-angle glaucoma. It said no serious adverse events or dose-limiting toxicities were reported through day 56, and the monitoring board recommended dose escalation.
Editorial view
Editorial view: This provides an early checkpoint for human safety testing of epigenetic reprogramming.
Evidence and limitations
Small, open-label, sponsor-reported interim data do not establish efficacy, long-term safety, human age reversal, or lifespan extension.